C4 Therapeutics (CCCC) Stock Statistics & Valuation Metrics

C4 Therapeutics has a market cap or net worth of $295.66M. The enterprise value is $209.96M.

C4 Therapeutics has 97,578,180 shares outstanding. The number of shares has decreased by -2.65% in one year.

C4 Therapeutics’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -31.43%.

The current PE Ratio of C4 Therapeutics is ―. C4 Therapeutics’s PEG ratio is 0.09.

In the last 12 months, C4 Therapeutics had revenue of 35.95M and earned -104.99M in profits. Earnings per share was -1.27.

In the last 12 months, operating cash flow was -98.69M and capital expenditures -607.00K, giving a free cash flow of -99.30M billion.

C4 Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

C4 Therapeutics upcoming earnings date is May 13, 2026, After Close (Confirmed).

C4 Therapeutics as a current ratio of 7.81, with Debt / Equity ratio of 23.38%

In the past 12 months, C4 Therapeutics has paid 121.00K in taxes.

C4 Therapeutics EV to EBITDA ratio is -1.40, with an EV/FCF ratio of -1.45.

C4 Therapeutics has $248.54M in cash and marketable securities with $59.98M in debt, giving a net cash position of $188.56M billion.

Gross margin is 94.98%, with operating margin of -290.68%, and net profit margin of -292.08%.

The average price target for C4 Therapeutics is $12.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy